Literature DB >> 21522124

Treatment of multiple myeloma.

S Vincent Rajkumar1.   

Abstract

The treatment of multiple myeloma has changed dramatically in the past decade. The increase in the number of active agents has generated numerous possible drug combinations that can be used in the first-line and relapsed settings. As a result, there is considerable confusion about the choice of regimens for initial therapy, role of transplantation in the era of new drugs, end points for therapy, and the role of maintenance therapy. A hotly debated area is whether treatment approaches should achieve cure or disease control, which impacts greatly on the treatment strategy employed. This article provides an update on the treatment of multiple myeloma, with a focus on recent advances, newly diagnosed disease, role of transplantation and maintenance therapy. A synthesized approach to the treatment of myeloma is presented, along with a discussion of key paradigms that need to be challenged.

Entities:  

Mesh:

Year:  2011        PMID: 21522124      PMCID: PMC3773461          DOI: 10.1038/nrclinonc.2011.63

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  80 in total

1.  Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.

Authors:  Frederic Garban; Michel Attal; Mauricette Michallet; Cyrille Hulin; Jean H Bourhis; Ibrahim Yakoub-Agha; Thierry Lamy; Gerald Marit; Frederic Maloisel; Christian Berthou; Mamoun Dib; Denis Caillot; Bernard Deprijck; Nicolas Ketterer; Jean-Luc Harousseau; Jean-Jacques Sotto; Philippe Moreau
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

2.  Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

Authors:  Bart Barlogie; Robert A Kyle; Kenneth C Anderson; Philip R Greipp; Hillard M Lazarus; David D Hurd; Jason McCoy; Dennis F Moore; Shaker R Dakhil; Keith S Lanier; Robert A Chapman; Jeana N Cromer; Sydney E Salmon; Brian Durie; John C Crowley
Journal:  J Clin Oncol       Date:  2006-01-23       Impact factor: 44.544

3.  Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.

Authors:  Michel Attal; Jean-Luc Harousseau; Serge Leyvraz; Chantal Doyen; Cyrille Hulin; Lofti Benboubker; Ibrahim Yakoub Agha; Jean-Henri Bourhis; Laurent Garderet; Brigitte Pegourie; Charles Dumontet; Marc Renaud; Laurent Voillat; Christian Berthou; Gerald Marit; Mathieu Monconduit; Denis Caillot; Bernard Grobois; Herve Avet-Loiseau; Philippe Moreau; Thierry Facon
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

4.  Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

Authors:  Jean-Luc Harousseau; Michel Attal; Xavier Leleu; Jacques Troncy; Brigitte Pegourie; Anne-Marie Stoppa; Cyrille Hulin; Lofti Benboubker; Jean-Gabriel Fuzibet; Marc Renaud; Philippe Moreau; Hervé Avet-Loiseau
Journal:  Haematologica       Date:  2006-10-17       Impact factor: 9.941

5.  Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

Authors:  María-Victoria Mateos; José-M Hernández; Miguel-T Hernández; Norma-C Gutiérrez; Luis Palomera; Marta Fuertes; Joaquín Díaz-Mediavilla; Juan-J Lahuerta; Javier de la Rubia; María-José Terol; Ana Sureda; Joan Bargay; Paz Ribas; Felipe de Arriba; Adrian Alegre; Albert Oriol; Dolores Carrera; José García-Laraña; Ramón García-Sanz; Joan Bladé; Felipe Prósper; Gemma Mateo; Dixie-Lee Esseltine; Helgi van de Velde; Jesús-F San Miguel
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

6.  Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.

Authors:  Thierry Facon; Jean-Yves Mary; Brigitte Pégourie; Michel Attal; Marc Renaud; Alain Sadoun; Laurent Voillat; Véronique Dorvaux; Cyrille Hulin; Gérard Lepeu; Jean-Luc Harousseau; Jean-Paul Eschard; Augustin Ferrant; Michel Blanc; Frédéric Maloisel; Hubert Orfeuvre; Jean-François Rossi; Isabelle Azaïs; Mathieu Monconduit; Philippe Collet; Bruno Anglaret; Ibrahim Yakoub-Agha; Marc Wetterwald; Houchingue Eghbali; Marie-Christine Vekemans; Hervé Maisonneuve; Jacques Troncy; Bernard Grosbois; Chantal Doyen; Antoine Thyss; Jérome Jaubert; Philippe Casassus; Béatrice Thielemans; Régis Bataille
Journal:  Blood       Date:  2005-09-20       Impact factor: 22.113

7.  Prevalence of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; Janice R Offord; Angela Dispenzieri; Jerry A Katzmann; L Joseph Melton
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

8.  A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

Authors:  Paul G Richardson; Emily Blood; Constantine S Mitsiades; Sundar Jagannath; Steven R Zeldenrust; Melissa Alsina; Robert L Schlossman; S Vincent Rajkumar; K Raman Desikan; Teru Hideshima; Nikhil C Munshi; Kathleen Kelly-Colson; Deborah Doss; Mary L McKenney; Svetlana Gorelik; Diane Warren; Andrea Freeman; Rebecca Rich; Anfang Wu; Marta Olesnyckyj; Kenton Wride; William S Dalton; Jerome Zeldis; Robert Knight; Edie Weller; Kenneth C Anderson
Journal:  Blood       Date:  2006-07-13       Impact factor: 22.113

9.  Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

Authors:  Antonio Palumbo; Sara Bringhen; Tommaso Caravita; Emanuela Merla; Vincenzo Capparella; Vincenzo Callea; Clotilde Cangialosi; Mariella Grasso; Fausto Rossini; Monica Galli; Lucio Catalano; Elena Zamagni; Maria Teresa Petrucci; Valerio De Stefano; Manuela Ceccarelli; Maria Teresa Ambrosini; Ilaria Avonto; Patrizia Falco; Giovannino Ciccone; Anna Marina Liberati; Pellegrino Musto; Mario Boccadoro
Journal:  Lancet       Date:  2006-03-11       Impact factor: 79.321

10.  A comparison of allografting with autografting for newly diagnosed myeloma.

Authors:  Benedetto Bruno; Marcello Rotta; Francesca Patriarca; Nicola Mordini; Bernardino Allione; Fabrizio Carnevale-Schianca; Luisa Giaccone; Roberto Sorasio; Paola Omedè; Ileana Baldi; Sara Bringhen; Massimo Massaia; Massimo Aglietta; Alessandro Levis; Andrea Gallamini; Renato Fanin; Antonio Palumbo; Rainer Storb; Giovannino Ciccone; Mario Boccadoro
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245

View more
  113 in total

1.  Haematological cancer: Lenalidomide maintenance--perils of a premature denouement.

Authors:  S Vincent Rajkumar
Journal:  Nat Rev Clin Oncol       Date:  2012-06-05       Impact factor: 66.675

2.  The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival.

Authors:  K S Bommert; M Effenberger; E Leich; M Küspert; D Murphy; C Langer; R Moll; S Janz; A Mottok; S Weissbach; A Rosenwald; R Bargou; K Bommert
Journal:  Leukemia       Date:  2012-07-09       Impact factor: 11.528

3.  High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.

Authors:  Christa E Nath; Judith Trotman; Campbell Tiley; Peter Presgrave; Douglas Joshua; Ian Kerridge; Yiu Lam Kwan; Howard Gurney; Andrew J McLachlan; John W Earl; Ian Nivison-Smith; Lihua Zeng; Peter J Shaw
Journal:  Br J Clin Pharmacol       Date:  2016-04-27       Impact factor: 4.335

Review 4.  Update on risk stratification and treatment of newly diagnosed multiple myeloma.

Authors:  Prashant Kapoor; S Vincent Rajkumar
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

5.  Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013.

Authors:  Maira A Castañeda-Avila; Karen J Ortiz-Ortiz; Carlos R Torres-Cintrón; Brenda M Birmann; Mara M Epstein
Journal:  Int J Cancer       Date:  2019-03-30       Impact factor: 7.396

Review 6.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

7.  The clinical significance of cereblon expression in multiple myeloma.

Authors:  Steven R Schuster; K Martin Kortuem; Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; Laura A Bruins; Jessica E Schmidt; Greg Ahmann; Shaji Kumar; S Vincent Rajkumar; Joseph Mikhael; Betsy Laplant; Mia D Champion; Kristina Laumann; Bart Barlogie; Rafael Fonseca; P Leif Bergsagel; Martha Lacy; A Keith Stewart
Journal:  Leuk Res       Date:  2013-09-05       Impact factor: 3.156

8.  Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Authors:  Maria T Di Martino; Emanuela Leone; Nicola Amodio; Umberto Foresta; Marta Lionetti; Maria R Pitari; Maria E Gallo Cantafio; Annamaria Gullà; Francesco Conforti; Eugenio Morelli; Vera Tomaino; Marco Rossi; Massimo Negrini; Manlio Ferrarini; Michele Caraglia; Masood A Shammas; Nikhil C Munshi; Kenneth C Anderson; Antonino Neri; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2012-10-03       Impact factor: 12.531

9.  CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

Authors:  Julia Bluhm; Elisa Kieback; Stephen F Marino; Felix Oden; Jörg Westermann; Markus Chmielewski; Hinrich Abken; Wolfgang Uckert; Uta E Höpken; Armin Rehm
Journal:  Mol Ther       Date:  2018-06-18       Impact factor: 11.454

10.  In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.

Authors:  DE-Jun Guo; Jia-Shan Han; Yan-Song Li; Zeng-Shan Liu; Shi-Ying Lu; Hong-Lin Ren
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.